Thomas Chalberg
Founder at Polymerase Capital
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Genine Winslow | F | - |
Chameleon Biosciences, Inc.
 Chameleon Biosciences, Inc. BiotechnologyHealth Technology Chameleon Biosciences, Inc. engages in the provision of a pre-clinical stage gene therapy. The company was founded by Genine Winslow and Jeffery Scott Vick and is headquartered in Berkeley, CA. | - |
| Jeffery Scott Vick | M | - |
Chameleon Biosciences, Inc.
Chameleon Biosciences, Inc. BiotechnologyHealth Technology Chameleon Biosciences, Inc. engages in the provision of a pre-clinical stage gene therapy. The company was founded by Genine Winslow and Jeffery Scott Vick and is headquartered in Berkeley, CA. | - |
| Carsten Rudolph | M | - |
ETHRIS GmbH
 ETHRIS GmbH Miscellaneous Commercial ServicesCommercial Services ETHRIS GmbH is a German company that specializes in developing innovative therapies and vaccines using its proprietary messenger RNA technology platform. The company is based in Planegg, Germany. The company is a leader in delivering stabilized mRNA directly to the respiratory system via optimized formulation and nebulization technologies. ETHRIS is rapidly advancing its pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients' lives. The company was founded by Carsten Rudolph and Christian Plank, and Carsten Rudolph has been the CEO since incorporation. | - |
| Christian Plank | M | - |
ETHRIS GmbH
ETHRIS GmbH Miscellaneous Commercial ServicesCommercial Services ETHRIS GmbH is a German company that specializes in developing innovative therapies and vaccines using its proprietary messenger RNA technology platform. The company is based in Planegg, Germany. The company is a leader in delivering stabilized mRNA directly to the respiratory system via optimized formulation and nebulization technologies. ETHRIS is rapidly advancing its pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients' lives. The company was founded by Carsten Rudolph and Christian Plank, and Carsten Rudolph has been the CEO since incorporation. | - |
| Karsten Henco | M | - |
ETHRIS GmbH
ETHRIS GmbH Miscellaneous Commercial ServicesCommercial Services ETHRIS GmbH is a German company that specializes in developing innovative therapies and vaccines using its proprietary messenger RNA technology platform. The company is based in Planegg, Germany. The company is a leader in delivering stabilized mRNA directly to the respiratory system via optimized formulation and nebulization technologies. ETHRIS is rapidly advancing its pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients' lives. The company was founded by Carsten Rudolph and Christian Plank, and Carsten Rudolph has been the CEO since incorporation. | - |
| Jackson Streeter | M | - |
Genascence Corp.
 Genascence Corp. BiotechnologyHealth Technology Genascence Corp. develops gene therapy products for musculoskeletal diseases. The company was founded by Dr. Annahita Keravala and Dr. Thomas W. Chalberg in 2017 and is headquartered in Palo Alto, CA. | 2 years |
| Winnie H. Wan | M | - |
Chameleon Biosciences, Inc.
Chameleon Biosciences, Inc. BiotechnologyHealth Technology Chameleon Biosciences, Inc. engages in the provision of a pre-clinical stage gene therapy. The company was founded by Genine Winslow and Jeffery Scott Vick and is headquartered in Berkeley, CA. | 5 years |
| Brian Kotzin | M | 74 |
Genascence Corp.
Genascence Corp. BiotechnologyHealth Technology Genascence Corp. develops gene therapy products for musculoskeletal diseases. The company was founded by Dr. Annahita Keravala and Dr. Thomas W. Chalberg in 2017 and is headquartered in Palo Alto, CA. | - |
| Gerd Maass | M | - |
ETHRIS GmbH
ETHRIS GmbH Miscellaneous Commercial ServicesCommercial Services ETHRIS GmbH is a German company that specializes in developing innovative therapies and vaccines using its proprietary messenger RNA technology platform. The company is based in Planegg, Germany. The company is a leader in delivering stabilized mRNA directly to the respiratory system via optimized formulation and nebulization technologies. ETHRIS is rapidly advancing its pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients' lives. The company was founded by Carsten Rudolph and Christian Plank, and Carsten Rudolph has been the CEO since incorporation. | - |
| Justin Duckworth | M | - |
ETHRIS GmbH
ETHRIS GmbH Miscellaneous Commercial ServicesCommercial Services ETHRIS GmbH is a German company that specializes in developing innovative therapies and vaccines using its proprietary messenger RNA technology platform. The company is based in Planegg, Germany. The company is a leader in delivering stabilized mRNA directly to the respiratory system via optimized formulation and nebulization technologies. ETHRIS is rapidly advancing its pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients' lives. The company was founded by Carsten Rudolph and Christian Plank, and Carsten Rudolph has been the CEO since incorporation. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Hans Hull | M | 49 | 4 years | |
| Mark Blumenkranz | M | 73 | 10 years | |
| Mehdi Gasmi | M | 57 | 6 years | |
| Linda Bain | F | 53 | 1 years | |
| Jennifer Cheng | M | 51 | 4 years | |
| John McLaughlin | M | 72 | 2 years | |
| Mitchell Finer | M | 65 | 13 years | |
| Paul Wachter | M | 67 | - | |
| Samuel Barone | M | 51 | 3 years | |
| Shirley Braun | M | - | 1 years | |
| Roman Rubio | M | 53 | 2 years | |
| Calvin Yu | M | 48 | 2 years | |
| Sunny Lee Ryan | F | 54 | 1 years | |
| Kee-Hong Kim | M | - | 2 years | |
| Elizabeth Alcamo | F | - | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 20 | 80.00% |
| Germany | 5 | 20.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Thomas Chalberg
- Personal Network
